Adaptive Biotechnologies(US:ADPT) Globenewswireยท2025-10-15 20:05Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A conference call will follow the financial results announcement, starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on utilizing the adaptive immune system's biology to develop clinical products for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system to enhance its diagnostic and therapeutic capabilities, which have been underutilized due to previous decoding challenges [3] - The proprietary immune medicine platform of the company allows for the translation of the adaptive immune system's genetics with scale, precision, and speed [3] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, providing products and clinical pipelines for diseases like cancer and autoimmune disorders [3] - The goal is to create and commercialize immune-driven clinical products tailored to individual patients [3]